Related references
Note: Only part of the references are listed.Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Martin C. Mueller et al.
BLOOD (2009)
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
Elias Jabbour et al.
BLOOD (2009)
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
Simona Soverini et al.
BLOOD (2009)
Mesenchymal stem cells: the fibroblasts' new clothes?
Muzlifah A. Haniffa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
Jane F. Apperley et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Timothy Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Sara Redaelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
Elias Jabbour et al.
BLOOD (2008)
The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene
Pin-Yi Wang et al.
BLOOD (2008)
Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL
Charles G. Mullighan et al.
GENES & DEVELOPMENT (2008)
Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene
Marta Baranska et al.
JOURNAL OF APPLIED GENETICS (2008)
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression
Jamshid S. Khorashad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
Neil P. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase
Ji Wu et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR)
S. Preuner et al.
LEUKEMIA (2008)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
Philipp le Coutre et al.
BLOOD (2008)
Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors
V. Nardi et al.
ONCOGENE (2008)
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Jorge Cortes et al.
BLOOD (2007)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M. Kantarjian et al.
BLOOD (2007)
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Jane F. Apperley
LANCET ONCOLOGY (2007)
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O'Hare et al.
BLOOD (2007)
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P. Shah et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Heike Pfeifer et al.
BLOOD (2007)
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
Arghya Ray et al.
BLOOD (2007)
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Francois Guilhot et al.
BLOOD (2007)
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
Jorge Cortes et al.
BLOOD (2007)
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Andreas Hochhaus et al.
BLOOD (2007)
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
Simona Soverini et al.
HAEMATOLOGICA (2007)
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
D. W. Sherbenou et al.
LEUKEMIA (2007)
High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations
A. Vivante et al.
LEUKEMIA (2007)
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants
Brian J. Skaggs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia
Simona Soverini et al.
CLINICAL CANCER RESEARCH (2006)
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice
Yiguo Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Comparison of imatinib, mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen:: high efficacy of drug combinations
Heather A. Bradeen et al.
BLOOD (2006)
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E. Jabbour et al.
LEUKEMIA (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the AN kinase inhibitor nilotinib (AMN107)
Nikolas von Bubnoff et al.
BLOOD (2006)
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib
Ian J. Griswold et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
E. Weisberg et al.
BRITISH JOURNAL OF CANCER (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients:: a retrospective analysis from the French intergroup of CML (Fi(φ)-LMC GROUP)
F. E. Nicolini et al.
LEUKEMIA (2006)
The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib
C Miething et al.
LEUKEMIA (2006)
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib
JS Khorashad et al.
LEUKEMIA (2006)
Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia
PW Manley et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2005)
Selecting and deselecting imatinib-resistant clones:: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL
FXE Gruber et al.
LEUKEMIA (2005)
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients; correlation with clonal cytogenetic evolution but not response to therapy
SG Willis et al.
BLOOD (2005)
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia
S Soverini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance
MR Burgess et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
YG Hu et al.
NATURE GENETICS (2004)
Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment
SW Cowan-Jacob et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Mechanisms and implications of imatinib resistance mutations in BCR-ABL
V Nardi et al.
CURRENT OPINION IN HEMATOLOGY (2004)
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
S Branford et al.
BLOOD (2003)
Several Bcr-Ab1 kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
AS Corbin et al.
BLOOD (2003)
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL
M Azam et al.
CELL (2003)
Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis:: A sequential study in 42 patients
JC Hernández-Boluda et al.
EXPERIMENTAL HEMATOLOGY (2003)
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
CB Gambacorti-Passerini et al.
LANCET ONCOLOGY (2003)
Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571
WH Liu et al.
LEUKEMIA RESEARCH (2003)
Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy
A Hochhaus et al.
LEUKEMIA (2002)
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
S Roumiantsev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Chronic myelogenous leukemia: mechanisms underlying disease progression
AS Shet et al.
LEUKEMIA (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
S Branford et al.
BLOOD (2002)
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571:: a prospective study
N von Bubnoff et al.
LANCET (2002)
Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
WK Hofmann et al.
BLOOD (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
T Schindler et al.
SCIENCE (2000)